Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese People's Liberation Army, No 28, Fuxing Rd, 100853 Beijing, People's Republic of China.
Med Oncol. 2011 Dec;28 Suppl 1:S48-54. doi: 10.1007/s12032-010-9693-y. Epub 2010 Sep 25.
The purpose of this study was to evaluate the importance of biological markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC) One hundred and twelve consecutive patients with clinical stage III LABC who had received NCT with docetaxel and epirubicin from March 2006 to March 2009 were included in this retrospective study. The pre-NCT treatment expression levels of Ki-67 proliferation index, estrogen receptor (ER), progesterone receptor (PgR), epidermal growth factor receptor 2 (HER-2), Topoisomerase II alpha (Topo-II), and nm23-H1 were detected by immunohistochemistry (IHC). A total of 361 cycles were administered with the median number of three cycles per patient (range, 2-6). The pCR rate was 9.8% (95% CI, 4.3-15.3%). In univariate analysis, poor tumor differentiation, both negative of ER/PgR, negative Topo-II, and positive nm23-H1 were found to be significantly predictive of a pCR. ER/PgR status and nm23-H1 were significant for pCR on multivariate analysis (P = 0.006 and 0.025, respectively). ER/PgR status and nm23-H1 are independent predictive factors of pCR to neoadjuvant docetaxel plus epirubicin combination chemotherapy in patients with LABC.
本研究旨在评估生物标志物对预测局部晚期乳腺癌（LABC）患者新辅助化疗（NCT）病理完全缓解（pCR）的重要性。 112 例连续接受 NCT 治疗的临床 III 期 LABC 患者，于 2006 年 3 月至 2009 年 3 月接受了多西他赛和表柔比星的 NCT。通过免疫组织化学（IHC）检测 Ki-67 增殖指数、雌激素受体（ER）、孕激素受体（PgR）、表皮生长因子受体 2（HER-2）、拓扑异构酶 IIα（Topo-II）和 nm23-H1 的治疗前表达水平。共给予 361 个周期，中位数为每个患者 3 个周期（范围为 2-6）。pCR 率为 9.8%（95%CI，4.3-15.3%）。单因素分析发现，肿瘤分化不良、ER/PgR 均阴性、Topo-II 阴性和 nm23-H1 阳性均与 pCR 显著相关。ER/PgR 状态和 nm23-H1 在多因素分析中对 pCR 有显著意义（P = 0.006 和 0.025）。ER/PgR 状态和 nm23-H1 是 LABC 患者接受多西他赛联合表柔比星新辅助化疗 pCR 的独立预测因素。
